Hjem › Kræft (alle typer) › Oklahoma
Kræft (alle typer) kliniske forsøg i Oklahoma
15 studier for Kræft (alle typer) søger deltagere på steder i Oklahoma.
Byer i Oklahoma
Officiel studietekst (engelsk)
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 1. okt. 2026 · NCT07024784Registry Study for Radiation Therapy Outcomes
- Oklahoma Proton Center, Oklahoma City
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 29. sep. 2026 · NCT01255748Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06128551Prospective Study to Assess a Diagnostic Aid for Cancer
- Hightower Clinical, Oklahoma City
RekruttererObservationsstudie
Alder 45 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT07046260Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City
RekruttererFase 2/3
Alle aldre · Alle køn · Opdateret 18. sep. 2026 · NCT03435796A Phase 1/1b Study of IAM1363 in HER2 Cancers
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06253871Project: Every Child for Younger Patients With Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
RekruttererObservationsstudie
Op til 25 år · Alle køn · Opdateret 25. aug. 2026 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT06580314Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT07327489GEMINI-NSCLC: NSCLC Biomarker Study
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 5. feb. 2026 · NCT05236114Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Oklahoma University Stephenson Cancer Center, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. nov. 2025 · NCT05997017SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2025 · NCT05107674Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 6. maj 2025 · NCT05234177Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- OUHSC Stephenson Cancer Center, Oklahoma City
- Mercy Health Center - Oncology Hematology, Oklahoma City
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 27. nov. 2024 · NCT03860883Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.